When is group B strep (Streptococcus agalactiae) screening performed during pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Group B Streptococcus Screening During Pregnancy

All pregnant women should be screened for Group B Streptococcus (GBS) colonization at 36 0/7 to 37 6/7 weeks of gestation through vaginal-rectal swab culture. 1, 2

Standard GBS Screening Protocol

Timing of Screening

  • The optimal timing for GBS screening is between 36 0/7 and 37 6/7 weeks of gestation 2
    • This represents an updated recommendation from the previous 35-37 weeks window 3
    • This timing provides the best sensitivity and specificity for detecting women who will remain colonized at delivery 1

Collection Technique

  • Proper specimen collection is critical for accurate results:
    • Swab the lower vagina (vaginal introitus) followed by the rectum (through anal sphincter)
    • Use the same swab or two different swabs for both sites
    • Insert the swab approximately 2 cm into the vagina and 1 cm into the anus 4
    • Patients can perform their own swabs with appropriate instruction 1, 4

Processing

  • Collected specimens should be placed into a nonnutritive transport medium 1
  • Some centers may use nucleic acid amplification tests (NAATs) for detection of GBS in addition to standard cultures 5

Exceptions to Standard Screening

Women Who Do NOT Need Screening

  1. Women with GBS bacteriuria during current pregnancy

    • These women should receive intrapartum antibiotic prophylaxis without additional screening 3, 1
    • This applies regardless of the colony count (though a threshold of at least 10⁴ colony-forming units per mL is considered positive) 5
    • Prior treatment with oral antibiotics does not eliminate the need for intrapartum prophylaxis 1
  2. Women who previously delivered an infant with invasive GBS disease

    • These women should receive intrapartum antibiotic prophylaxis without screening 3, 1

Management Based on Screening Results

Positive GBS Screening

  • Intrapartum antibiotic prophylaxis should be given to all pregnant women who test positive for GBS colonization 3
  • Exception: Cesarean delivery performed before onset of labor on a woman with intact amniotic membranes 3, 1

Unknown GBS Status at Labor

Intrapartum antibiotic prophylaxis should be given when screening results are unavailable if any of these risk factors are present:

  • Delivery at <37 weeks' gestation
  • Amniotic membrane rupture ≥18 hours
  • Intrapartum temperature ≥100.4°F (≥38.0°C) 3

Common Pitfalls to Avoid

  1. Inappropriate timing of screening

    • Screening too early (before 36 weeks) or too late may reduce accuracy
  2. Improper collection technique

    • Failure to sample both vaginal and rectal sites reduces sensitivity
  3. Relying on previous pregnancy results

    • GBS status in a previous pregnancy does not predict current status unless there was a previous GBS-affected infant 1
  4. Using oral antibiotics before labor

    • Antimicrobial agents should not be used before the intrapartum period to eradicate GBS colonization, as this is ineffective and may cause adverse consequences 3
  5. Overlooking GBS bacteriuria

    • Women with GBS bacteriuria during any trimester require intrapartum prophylaxis regardless of subsequent screening results 1

Despite universal screening and prophylaxis protocols, GBS remains a significant cause of neonatal sepsis and mortality, highlighting the importance of adherence to screening guidelines 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.